Selank publications
The rat hippocampus paper is the starting point. The patient report and the laboratory assays take the question in different directions.
Hippocampal BDNF
Intranasal Selank and BDNF expression in rat hippocampus supplies the molecular starting point. The clinical report in generalized anxiety disorder describes anxiety and tolerability outcomes in patients. Preserved cognition is the question that joins them here. The measured outcomes remain different.
Cortex and plasma experiments
The rat GABA-related gene-expression experiment, the human-plasma enzyme assay and the Selank–Semax serum comparison pursue different biological processes. The separate immune study in patients with anxiety-asthenic disorders makes the biological picture broader still.
Full publication details follow. The publications below give this question its actual starting points.
- Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo ↗
- Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (selank) in the therapy of generalized anxiety disorders and neurasthenia ↗
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission ↗
- The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity ↗
- Immunomodulatory effects of selank in patients with anxiety-asthenic disorders ↗
- Semax and selank inhibit the enkephalin-degrading enzymes from human serum ↗